Kumthekar, Priya
Lyleroehr, Madison
Lacson, Leilani
Lukas, Rimas V.
Dixit, Karan
Stupp, Roger
Kruser, Timothy
Raizer, Jeff
Hou, Alexander
Sachdev, Sean
Schwartz, Margaret
PA, Jessica Bajas
Lezon, Ray
Schmidt, Karyn
Amidei, Christina
Kaiser, Karen
Funding for this research was provided by:
Novocure
Article History
Received: 29 September 2023
Accepted: 22 February 2024
First Online: 25 April 2024
Declarations
:
: The study protocol was approved by the institutional review board of Northwestern University (STU00210799) and all patients enrolled on study provided written informed consent prior to any study-related procedures.
: Not applicable.
: PK has received research and grant support from Genentech, Novocure, DNAtrix and Orbus Therapeutics. PK has served on medical advisory boards for Biocept, Sintetica, Novocure, Janssen, Affinia, Celularity, and SDP Oncology. PK has provided consulting to Bliss Bio, Biocept, Enclear Therapies, Angiochem, Affinia Therapeutics. TK serves on an advisory board and speakers bureau for AstraZeneca, and a consultant for Radialogica LLC, none of which relate to this work. MS is in the Novocure speakers bureau. RVL serves on the speakers’ bureaus for Novocure and Merck. RVL has received research support (drug only) from BMS. RVL has received honoraria for medical editing for EBSCO Publishing, and Medlink Neurology. RVL also serves on advisory boards for Novocure, AstraZeneca, Cardinal Health, Servier, and Merck. SS has served on advisory boards for Lantheus, Astellas, and Pfizer. KK has served as a consultant for PTC Therapeutics. All other authors declare no competing interests.